Glucose Monitoring Devices Market to Reach US$ 67.74 Billion by 2033 at 17.0% CAGR; Rising Diabetes Prevalence and CGM Adoption Drive Growth

The global Glucose Monitoring Devices Market reached US$ 16.65 billion in 2024 and is expected to reach US$ 67.74 billion by 2033, growing at a CAGR of 17.0% during the forecast period 2025-2033. Market growth is driven by the increasing prevalence of diabetes worldwide, fueled by aging populations, sedentary lifestyles, and unhealthy dietary patterns, which are creating strong demand for accurate and efficient blood glucose monitoring solutions.

Glucose monitoring devices, including Continuous Glucose Monitoring (CGM) systems and Self-Monitoring of Blood Glucose (SMBG) devices, play a critical role in effective diabetes management by enabling real-time tracking of blood glucose levels. Technological advancements such as non-invasive and wearable sensors, smartphone connectivity, cloud-based data platforms, and AI-driven analytics are significantly improving device accuracy, usability, and patient adherence. Supportive government policies, favorable reimbursement frameworks in developed markets, and public-private collaborations in emerging economies are accelerating adoption. North America remains a key market due to high diabetes prevalence and advanced digital health adoption, while expanding healthcare infrastructure and rising awareness are supporting sustained growth across other regions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glucose-monitoring-devices-market?sai-v

The Glucose Monitoring Devices Market refers to the global industry focused on the development and commercialization of devices used to measure and track blood glucose levels for diabetes management.

Key Developments
✅ January 2026: In North America, adoption of continuous glucose monitoring (CGM) systems increased among Type 1 and Type 2 diabetes patients due to improved sensor accuracy and expanded insurance coverage.

✅ December 2025: In Europe, integration of glucose monitoring data with telehealth platforms expanded, supporting remote diabetes management and clinician oversight.

✅ November 2025: In Asia-Pacific, demand rose for affordable self-monitoring blood glucose (SMBG) devices in emerging markets to enhance diabetes screening and daily monitoring.

✅ October 2025: In Latin America, healthcare providers began deploying hybrid CGM systems in outpatient clinics to support intensive insulin therapy programs.

✅ September 2025: In the Middle East, community health initiatives emphasized early detection of prediabetes using portable glucose monitors to reduce long-term complications.

✅ August 2025: In Africa, pilot programs introduced low-cost glucose monitors in rural care settings to improve access and patient adherence.

Mergers & Acquisitions
✅ January 2026: In North America, a major diabetes technology company acquired a wearable sensor startup to strengthen its continuous glucose monitoring portfolio.

✅ December 2025: In Europe, a leading medical device manufacturer acquired a cloud-connected glucose analytics platform provider to enhance data integration and remote monitoring capabilities.

✅ November 2025: In Asia-Pacific, a regional healthcare group acquired a distributor of glucose monitoring products to expand market reach in emerging economies.

Key Players
Abbott Laboratories | Medtronic | F. Hoffmann-La Roche Ltd | LifeScan IP Holdings, LLC | Sanofi SA | B. Braun Melsungen AG | Dexcom | Senseonics, Inc. | Nova Biomedical Corporation | Omnis Health LLC

Key Highlights
Abbott Laboratories - Holds 32.4% share, driven by global leadership in continuous glucose monitoring systems, strong adoption of FreeStyle platforms, and wide reimbursement coverage across major markets.

Dexcom - Holds 21.6% share, supported by advanced real-time continuous glucose monitoring technology, strong presence in Type 1 diabetes management, and rapid growth in digital health integration.

Medtronic - Holds 15.2% share, leveraging integrated insulin pump and glucose monitoring ecosystems, strong clinical validation, and global distribution capabilities.

F. Hoffmann-La Roche Ltd - Holds 11.8% share, driven by long-standing dominance in blood glucose monitoring strips and meters, with strong brand trust among patients and clinicians.

LifeScan IP Holdings, LLC - Holds 7.4% share, supported by the OneTouch product portfolio, wide retail availability, and strong presence in self-monitoring blood glucose devices.

Sanofi SA - Holds 4.3% share, benefiting from diabetes care solutions and device-assisted therapy support aligned with pharmaceutical diabetes treatments.

Senseonics, Inc. - Holds 3.2% share, focused on implantable continuous glucose monitoring systems offering long-term wear and differentiated patient value.

Nova Biomedical Corporation - Holds 2.3% share, specializing in hospital-based glucose monitoring systems and point-of-care diagnostics.

B. Braun Melsungen AG - Holds 1.9% share, contributing through diabetes care consumables and integrated hospital glucose management solutions.

Omnis Health LLC - Holds 0.9% share, focused on niche glucose monitoring devices and regional market presence.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=glucose-monitoring-devices-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rising global prevalence of diabetes increasing the need for continuous and self-monitoring of blood glucose levels.

- Growing adoption of continuous glucose monitoring systems for improved glycemic control and real-time data access.

- Increasing awareness about diabetes management, preventive care, and early diagnosis among patients and healthcare providers.

- Technological advancements in sensor accuracy, minimally invasive monitoring, and wearable device integration.

- Expansion of home healthcare and remote patient monitoring solutions supporting long-term diabetes management.

Industry Developments
- Continuous innovation in continuous glucose monitoring and flash glucose monitoring technologies.

- Integration of glucose monitoring devices with smartphones, insulin pumps, and digital diabetes management platforms.

- Development of smaller, more accurate, and longer-wear sensors to improve patient comfort and compliance.

- Strategic partnerships between device manufacturers and digital health companies to enhance data analytics and connectivity.

- Expansion of manufacturing and distribution networks to meet rising global demand.

Regional Insights
North America - 36% share: "Driven by high diabetes prevalence, strong reimbursement support, advanced healthcare infrastructure, and widespread adoption of continuous glucose monitoring systems."

Europe - 27% share: "Supported by established diabetes care programs, rising adoption of advanced monitoring devices, and strong regulatory frameworks."

Asia Pacific - 31% share: "Fueled by large diabetic population, expanding healthcare access, increasing awareness of diabetes management, and growing adoption of cost-effective monitoring solutions."

Latin America - 4% share: "Driven by improving diabetes diagnosis rates, expansion of healthcare services, and increasing availability of glucose monitoring devices."

Middle East & Africa - 2% share: "Supported by rising diabetes burden, healthcare infrastructure development, and increasing focus on chronic disease management."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glucose-monitoring-devices-market?sai-v

Key Segments

By Product Type
Self-monitoring blood glucose devices hold a significant share of the market, driven by widespread use of blood glucose meters and test strips for routine diabetes management. Continuous glucose monitoring devices are witnessing rapid growth, supported by increasing adoption of real-time glucose tracking, improved sensor accuracy, and rising preference for connected and wearable solutions.

By Indication
Type 2 diabetes represents the largest indication segment, driven by high disease prevalence and long-term monitoring requirements. Type 1 diabetes holds a substantial share, supported by continuous glucose monitoring adoption and intensive insulin management. Gestational diabetes contributes notably due to rising awareness and increased screening during pregnancy.

By End User
Home care settings dominate the end-user segment, driven by convenience, self-monitoring needs, and growing patient awareness. Hospitals hold a significant share, supported by inpatient glucose monitoring and critical care applications. Clinics and diagnostic centers contribute steadily through outpatient diabetes management and monitoring services.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.